Benzinga | Aug 2, 2021 04:38PM EDT

Personalis Highlights Publication Of Its Study 'Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mechanisms' In Clinical Cancer Research Journal

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study "Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mechanisms,"(1) in Clinical Cancer Research, a journal published by the American Association for Cancer Research.